Outlook Therapeutics, Inc. (OTLK) Tops Q2 EPS by 9c

Outlook Therapeutics, Inc. (NASDAQ: OTLK) reported Q2 EPS of ($0.89), $0.09 better than the analyst estimate of ($0.98).

For earnings history and earnings-related data on Outlook Therapeutics, Inc. (OTLK) click here.

You May Also Be Interested In

• Gap taps Coach architect Reed Krakoff for $29.95-$498 handbag line
• Edison International (EIX) PT Lowered to $63 at UBS
• UBS Reiterates Buy Rating on SLB (SLB)